Terry Matkovits: Sure, I’d be happy to. So we have agreed and supported the compassionate use of MAT2203 for the treatment of 5 patients, 4 of whom have had very favorable responses, both from a safety and an efficacy perspective. All of the patients who have been put forward as compassionate use patients have had significant renal toxicity associated with their IV administered IV amphotericin. And these were patients for whom there were no other treatment options. So they were clinically responding to the IV-administered amphotericin but had significant renal toxicity which is why they were coming to us for our support. I’m very happy to be able to share with you that 2 of the patients have completed treatment and have successfully responded to treatment.
The first patient which will be presented as an oral presentation at ECCMID had an osteomyelitis, so a bone infection in her left foot and was at risk for amputation. She had a Rhodotorula infection that was not — she was not able to continue IV amphotericin because she had significant renal failure. Upon transitioning to our oral MAT2203, she had continued clinical response such that we were able to save her foot. She was able to resume normal weight-bearing activity and very importantly, the renal dysfunction and toxicity was completely reversed once she transitioned to our oral MAT2203. And now after 3 to 4 months of treatment, she’s completely clinically — her infection is completely clinically resolved. The second patient had a candida infection in his bladder after only 2 weeks of transitioning on to oral MAT2203.
He also had complete clinical resolution of his symptoms. The other 2 patients continue to improve on MAT2203. One of the patients who is severely — presented with severe aspergillosis and mucormycosis is continuing to improve on treatment. This is a chemotherapy patient who was again significantly ahead of safety risk with the IV amphotericin that she was receiving. After transitioning to our drug, she has been clinically improving and has had very favorable response both for her aspergillosis as well as her mucor infection. And the fourth patient, who is continuing to receive MAT2203, has a mucocutaneous infection who’s also responding very well to treatment.
Operator: There are no further questions at this time. I’d like to turn the floor back over to Jerry Jabbour for any closing comments.
Jerry Jabbour: Thanks, Paul. Thank you once again for joining us today and for your interest in Matinas BioPharma. We’re very excited about our company’s future and look forward to reporting progress during our Q1 investor call, a short time from now in May. Thanks and have a great evening.
Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.